Overview

A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia

Status:
NOT_YET_RECRUITING

Trial end date:
2031-11-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to investigate the efficacy and safety of fixed-duration sonrotoclax (also known as BGB-11417) plus zanubrutinib (also known as BGB-3111) (SZ) compared with fixed-duration of venetoclax plus acalabrutinib (AV) in participants with previously untreated chronic lymphocytic leukemia (CLL).

Phase:

PHASE3

Details

Lead Sponsor:

BeOne Medicines

Treatments:

acalabrutinib
venetoclax
zanubrutinib